Medicare AdvantageCoverageMedium impact
MA07.056f, Photodynamic Therapy (PDT) Using Levulan® Kerastick® or Ameluz® (Aminolevulinic Acid HCl [ALA])
Independence Blue Cross·Dermatology, Oncology·Pharmacy
Effective date
Mar 4, 2026
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA07.056f regarding Photodynamic Therapy using Levulan Kerastick or Ameluz (aminolevulinic acid) has been reissued with an effective date of March 4, 2026. This is a fresh policy update that may contain changes to coverage or requirements for PDT procedures.
Action Required
Before March 4, 2026: Review the complete policy MA07.056f for Photodynamic Therapy using Levulan Kerastick or Ameluz to identify specific coverage changes, prior authorization requirements, or documentation updates. Update billing protocols and staff training accordingly for Medicare Advantage plans.